Infographic on protecting yourself and the most vulnerable against respiratory viruses.

As Europe enters the autumn and winter months, respiratory infections are expected to considerably affect the health of individuals vulnerable to severe outcomes. Young children,

We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European

During the first year of the COVID-19 pandemic, vaccination programmes targeted children and adolescents to prevent severe outcomes of SARS-CoV-2 infection.AimTo estimate COVID-19 vaccine effectiveness

There is still widespread circulation of COVID-19 in the EU/EEA, although it is decreasing. RSV and influenza transmission remain low — for now. Consider getting

Communications materials, toolkits and guidelines on COVID-19.

In the EU/EEA, widespread but decreasing circulation of SARS-CoV-2 is observed, with limited impact on hospitalisations. Respiratory syncytial virus and influenza circulation remain at low

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 4 -11 October 2025 and includes updates on respiratory virus epidemiology in

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 26 September – 3 October 2025 and includes updates on respiratory viruses,

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 30 August – 5 September 2025 and includes updates on Salmonella Strathcona,

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 2 – 8 August 2025 and includes updates on influenza A(H5N1), measles,

This issue of the CDTR covers the period 26 July−1 August 2025 and includes updates on dengue, mpox, chikungunya virus disease, Crimean-Congo haemorrhagic fever, West